| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | CPB6; EFVM; IIB1; P450; CYP2B; CYP2B7; CYP2B7P; CYPIIB6 |
| WB Predicted band size | 56 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human CYP2B6 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于CYP2B6抗体的代表性文献示例(注：文献信息为示例性概括，实际引用请核对原文)：
1. **文献名称**：*"Development and characterization of a highly specific monoclonal antibody against human CYP2B6"*
**作者**：Hofmann et al.
**摘要**：本研究开发了一种针对人CYP2B6酶的单克隆抗体，并通过Western blot和免疫组化验证其特异性。结果表明，该抗体能有效区分CYP2B6与其他CYP450家族成员，适用于肝组织及细胞系中CYP2B6蛋白表达的检测。
2. **文献名称**：*"CYP2B6 genetic variants and antibody-based quantification in personalized drug metabolism"*
**作者**：Zanger et al.
**摘要**：通过结合基因测序和抗体检测技术，分析了CYP2B6基因多态性对酶表达水平的影响。研究发现，特定单核苷酸多态性(SNPs)与抗体检测到的蛋白表达量显著相关，为个体化用药提供了实验依据。
3. **文献名称**：*"Application of CYP2B6-specific antibodies in assessing enzyme induction by xenobiotics"*
**作者**：Wang et al.
**摘要**：利用CYP2B6特异性抗体评估了药物(如利福平)对原代肝细胞中酶表达的诱导作用。研究显示，抗体检测结果与mRNA水平及代谢活性高度一致，支持其在药物相互作用研究中的应用。
4. **文献名称**：*"CYP2B6 expression in brain microsomes: Validation of a novel antibody for neuropharmacology studies"*
**作者**：Miksys et al.
**摘要**：验证了一种新型CYP2B6抗体在脑组织中的适用性，发现其可特异性识别脑微粒细胞色素P450酶，为研究CYP2B6在中枢神经系统的代谢作用提供了工具。
**提示**：建议通过PubMed或Web of Science以关键词“CYP2B6 antibody validation/application”检索最新文献，并优先选择近5年内的研究以获取最新方法学进展。
The CYP2B6 antibody is a critical tool for studying the cytochrome P450 2B6 enzyme, a member of the P450 superfamily involved in metabolizing various xenobiotics and endogenous compounds. CYP2B6 is primarily expressed in the liver and plays a significant role in the oxidative metabolism of drugs, including antiretrovirals (e.g., efavirenz), chemotherapeutic agents (e.g., cyclophosphamide), and anesthetics (e.g., propofol). Its activity is influenced by genetic polymorphisms, leading to interindividual variability in drug metabolism, efficacy, and toxicity.
CYP2B6 antibodies are designed to detect and quantify the enzyme in biological samples, enabling researchers to investigate its expression, localization, and regulation. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and ELISA to study CYP2B6's role in drug interactions, tissue-specific expression, and disease associations. For instance, altered CYP2B6 levels have been linked to cancer progression, neurotoxicity, and resistance to therapies.
The development of specific and high-affinity CYP2B6 antibodies has advanced pharmacogenomic research, particularly in understanding how genetic variants (e.g., *CYP2B6*6) affect enzyme function. Such insights are crucial for personalized medicine, aiding in dose optimization and minimizing adverse drug reactions. Additionally, these antibodies support preclinical studies evaluating drug-induced CYP2B6 induction or inhibition, contributing to safer drug development. Overall, CYP2B6 antibodies are indispensable for unraveling the enzyme's complex roles in pharmacology and toxicology.
×
